000278790 001__ 278790
000278790 005__ 20250604100730.0
000278790 0247_ $$2doi$$a10.3389/fneur.2025.1594382
000278790 0247_ $$2pmid$$apmid:40386019
000278790 0247_ $$2pmc$$apmc:PMC12081243
000278790 037__ $$aDZNE-2025-00626
000278790 041__ $$aEnglish
000278790 082__ $$a610
000278790 1001_ $$0P:(DE-2719)9000867$$aPurrer, Veronika$$b0$$eFirst author$$udzne
000278790 245__ $$aQuantitative and qualitative tremor evaluation after MR-guided focused ultrasound thalamotomy.
000278790 260__ $$aLausanne$$bFrontiers Research Foundation$$c2025
000278790 3367_ $$2DRIVER$$aarticle
000278790 3367_ $$2DataCite$$aOutput Types/Journal article
000278790 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748939212_16670
000278790 3367_ $$2BibTeX$$aARTICLE
000278790 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000278790 3367_ $$00$$2EndNote$$aJournal Article
000278790 520__ $$aTremor syndromes are common neurological disorders, usually distinguished by clinical examination. Ordinal rating scales are widely used to rate tremor severity but are limited by subjective observation, interrater reliability, ceiling effects and lack of knowledge about sensitivity to change emphasizing the relevance of quantitative methods.To assess tremor characteristics in essential tremor (ET) and Parkinson's disease tremor (PT) quantitatively, we used a wearable triaxial accelerometer in comparison to a common clinical rating scale. Furthermore, different activation conditions and changes after treatment with MR-guided focused ultrasound (MRgFUS) were examined concomitantly. Patients with disabling, medication-refractory ET (n = 35) or PT (n = 21) undergoing unilateral MRgFUS thalamotomy were assessed before, 1, 6 and 12 months after MRgFUS treatment. Clinical assessments included the Clinical Rating Scale for Tremor (CRST) and accelerometric recordings at rest, posture and kinetic movement. Peak frequencies (fp), frequency width at half maximum (FWHM), tremor stability index (TSI), and half-width power (HWP) were extracted from the power spectrum of acceleration and compared to the CRST.We observed moderate to strong correlations between CRST subscores and log-transformed HWP, whereas significant correlations were only evident in ET when groups were evaluated separately. Fp, FWHM and TSI showed no differences between groups and conditions. Further, repeated measurements after MRgFUS treatment revealed significant changes of tremor severity in both, clinical rating and accelerometric recordings.Tremor assessment using accelerometric recordings provided a fast and investigator independent method for tremor characterization and quantitative assessment, which were sensitive to changes after therapeutic interventions.
000278790 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000278790 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000278790 650_7 $$2Other$$aMRgFUS
000278790 650_7 $$2Other$$aaccelerometry
000278790 650_7 $$2Other$$aquantitative measurements
000278790 650_7 $$2Other$$athalamotomy
000278790 650_7 $$2Other$$atremor
000278790 7001_ $$aChand, Tara$$b1
000278790 7001_ $$0P:(DE-2719)9003337$$aPohl, Emily$$b2$$udzne
000278790 7001_ $$aWeiland, Hannah$$b3
000278790 7001_ $$aBorger, Valeri$$b4
000278790 7001_ $$aSchmeel, Carsten$$b5
000278790 7001_ $$0P:(DE-2719)2810726$$aBoecker, Henning$$b6$$udzne
000278790 7001_ $$0P:(DE-2719)2000056$$aWüllner, Ullrich$$b7$$eLast author$$udzne
000278790 773__ $$0PERI:(DE-600)2564214-5$$a10.3389/fneur.2025.1594382$$gVol. 16, p. 1594382$$p1594382$$tFrontiers in neurology$$v16$$x1664-2295$$y2025
000278790 8564_ $$uhttps://pub.dzne.de/record/278790/files/DZNE-2025-00626.pdf$$yOpenAccess
000278790 8564_ $$uhttps://pub.dzne.de/record/278790/files/DZNE-2025-00626.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000278790 909CO $$ooai:pub.dzne.de:278790$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000278790 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000867$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000278790 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003337$$aExternal Institute$$b2$$kExtern
000278790 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810726$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000278790 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000056$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000278790 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000278790 9141_ $$y2025
000278790 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000278790 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000278790 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000278790 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROL : 2022$$d2025-01-07
000278790 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-01-11T07:34:54Z
000278790 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-01-11T07:34:54Z
000278790 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000278790 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
000278790 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000278790 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000278790 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000278790 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-01-11T07:34:54Z
000278790 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
000278790 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000278790 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000278790 9201_ $$0I:(DE-2719)1011302$$kAG Wüllner$$lBiomarker Parkinson's Disease$$x0
000278790 9201_ $$0I:(DE-2719)1011001$$kClinical Research (Bonn)$$lClinical Research Coordination$$x1
000278790 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x2
000278790 980__ $$ajournal
000278790 980__ $$aVDB
000278790 980__ $$aUNRESTRICTED
000278790 980__ $$aI:(DE-2719)1011302
000278790 980__ $$aI:(DE-2719)1011001
000278790 980__ $$aI:(DE-2719)1011202
000278790 9801_ $$aFullTexts